medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Smoking and SARS-CoV-2 Impair Dendritic Cells and Regulate DC-SIGN
Expression in Tissues
Guoshuai Cai1*, Yohan BossÃ©2, Mulong Du3,4, Helmut Albrecht5, Fei Qin6, Xuanxuan Yu6, Xizhi
Luo6, Michelle Androulakis7,8, Xia Zhu1, Jun Zhou1, Xiang Cui1, Changhua Yi9, Chao Cheng10,
Mitzi Nagarkatti11, Prakash Nagarkatti11, David Christiani3,12, Michael Whitfield13, Christopher
Amos10, Feifei Xiao4*

1

Department of Environmental Health Sciences, Arnold School of Public Health, University of

South Carolina, Columbia, SC, USA
2

Institut universitaire de cardiologie et de pneumologie de QuÃ©bec (IUCPQ), Department of

Molecular Medicine, Laval University, Quebec City, Canada
3

Departments of Environmental Health, Harvard T.H. Chan School of Public Health, Boston,

Massachusetts
4

Department of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical

University, Nanjing, China
5

Department of Internal Medicine, Prisma Health Medical Group, University of South Carolina,

Columbia, SC, USA
6

Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of

South Carolina, Columbia, SC, USA
7

Neurology, Columbia VA Health System, Columbia, SC, USA

8

Department of Neurology, School of Medicine, University of South Carolina, Columbia, SC,

USA
9

Nanjing Clinical Medical Center for Infectious Diseases, the Second Hospital of Nanjing,

Southeast University, Nanjing, China.
10

Institute for Clinical and Translational Research and Dan L. Duncan Comprehensive Cancer

Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
11

Department of Pathology, Microbiology and Immunology, School of Medicine, University of

South Carolina, Columbia, USA.
12

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts

13

Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon,

New Hampshire, USA.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

*Address correspondence to:
Guoshuai Cai
Department of Environmental Health Sciences
Arnold School of Public Health
University of South Carolina
915 Greene Street
Discovery 517
Columbia, SC 29204
GCAI@mailbox.sc.edu
Phone: 803-777-4120
Feifei Xiao
Department of Epidemiology and Biostatistics
Arnold School of Public Health
University of South Carolina
915 Greene Street
Discovery 449
Columbia, SC 29204
XIAOF@mailbox.sc.edu
Phone: 803-777-8936

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Graphical Abstract

Highlights
Smoking upregulates the expression of ACE2 and CD209 and inhibits DC maturation in lungs.
SARS-CoV-2 modulates the DCs proportion and CD209 expression differently in lung and
blood.
Severe infection is characterized by DCs less capable of maturation, antigen presentation and
MHCII expression.
DCs shift from cDCs to pDCs with SARS-CoV-2 infection but are trapped in an immature stage
in severe cases.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Summary
The current spreading novel coronavirus SARS-CoV-2 is highly infectious and pathogenic. In
this study, we screened the gene expression of three SARS-CoV-2 host receptors (ACE2, DCSIGN and L-SIGN) and DC status in bulk and single cell transcriptomic datasets of upper
airway, lung or blood of smokers, non-smokers and COVID-19 patients. We found smoking
increased DC-SIGN gene expression and inhibited DC maturation and its ability of T cell
stimulation. In COVID-19, DC-SIGN gene expression was interestingly decreased in lung DCs
but increased in blood DCs. Strikingly, DCs shifted from cDCs to pDCs in COVID-19, but the
shift was trapped in an immature stage (CD22+ or ANXA1+ DC) with MHCII downregulation in
severe cases. This observation indicates that DCs in severe cases stimulate innate immune
responses but fail to specifically recognize SARS-CoV-2. Our study provides insights into
smoking effect on COVID-19 risk and the profound modulation of DC function in severe COVID19.

Key words
ACE2, DC-SIGN, smoking, COVID-19, dendritic cells

Introduction
In 2020, a novel coronavirus SARS-CoV-2 has been spreading as a pandemic infection. SARSCoV-2 is highly infectious and pathogenic through human-to-human transmission and causes
severe Coronavirus Disease 2019 (COVID-19)1. COVID-19 critical cases are often
characterized by a pro-inflammatory â€œcytokine stormâ€ with a release of excessive cytokines

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

(including IL-6, IL-1, IL-2, IL-10, TNF-a and IFN-g and others) and a hyperactive immune
response which cause damage to target organs. Despite extensive research, the exact immune
pathophysiology of SARS-CoV-2 has remained elusive.
Coronavirus is a single-stranded RNA virus that can be divided into four main genres
including the alpha, beta, gamma and delta coronaviruses2. Studies showed that SARS-CoV-2
is closely related to SARS-CoV, with around 80% homology of genome3, belonging to the same
ğ›½-genus4, having similar receptor-binding domain (RBD) structures2 and causing similar clinical
symptoms including acute respiratory response5. Many viruses are capable of using alternative
receptors to enter host cells. This is also true for SARS coronavirus. Three receptorsâ€”ACE2,
DC-SIGN and L-SIGN (gene symbol as ACE2, CD209 and CLEC4M respectively) have been
found to be involved in the pathogenicity of SARS-CoV6-8. ACE2 was also been quickly
confirmed to be the receptor for SARS-CoV-29. Recently, DC-SIGN and L-SIGN were identified
as alternative receptors for mediating SARS-CoV-2 entry into human cells10.
In vivo, L-SIGN is largely expressed on endothelial cells in liver sinusoids and lymph nodes,
whereas DC-SIGN is mainly expressed on dendritic cells (DCs)11. Aside from epithelial cells,
SARS-CoV infection was found in T cells, macrophages (MÃ¸) and monocyte-derived dendritic
cells and this viral attack is probably responsible for the lymphopenia which was commonly
observed in patients with SARS-CoV infection12. While DC-SIGN and L-SIGN provide gateways
for SARS coronavirus to attack infected immune cells, they play important anti-viral roles. They
both capture, transmit and disseminate virus within the host13,14. With the dual roles of DC-SIGN
as a SARS-CoV-2 gateway and an innate immune initiator, DCs may play an important and
complicated role in OVID-19 patients and link to clinical phenotypes. Studies indicate a
decrease of conventional DCs (cDC) and plasmacytoid DCs (pDC) in the lung and blood of
severe COVID-19 cases15,16. Yet, comprehensive insights into modulation of DCs in tissues with
COVID-19 are still missing.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Environmental exposures might influence the COVID-19 risk by regulating receptors and
remodel immune cells. The clinical epidemiology data showing a higher risk of smokers of
developing a severe COVID-19 disease17. In agreement with that, we previously demonstrated
an upregulation of ACE2 in the lungs of smokers18. In this study, we further investigated the
effects of smoking on the gene expression of the two newly identified SARS-CoV-2 receptors
DC-SIGN and L-SIGN by analyzing large-scale bulk tissue datasets and high-granularity single
cell datasets of normal lung tissues. Also, we systematically studied the transcriptome
dysregulation in single cells in the upper airway (nasopharynx/pharynx samples), lower airway
(bronchoalveolar lavage fluid (BALF) samples) and peripheral blood (peripheral blood
mononuclear cell (PMBC) samples) of COVID-19 patients. These single cell datasets enabled
the investigation of variation of DC activation in smokers and non-smokers, as well as mild and
severe COVID-19 and healthy controls. In severe COVID-19, we found significantly decreased
DCs and its shift to immature subsets. The results illustrate the pathogenicity and virulence of
SARS-CoV-2 infection from the aspect of DCs which is a critical player in the immune response
to viral infection.

Results
Infection correlation and variation of immune factors in COVID-19 upper airway.
In the nasopharynx/pharynx samples of 238 patients with acute respiratory illnesses (ARIs), we
found ACE2 (P = 3.9 Ã— 10!"# ) and DC-SIGN (ğ‘ƒ = 0.048) gene expression were significantly
higher with the SARS-CoV-2 infection (Fig. S1). In addition, we found ACE2 gene expression
was strongly positively associated with the viral load of SARS-CoV-2 (ğ‘ƒ = 5.3 Ã— 10!$ ). No data
was available for CLEC4M. Notably, the gene expression of essential factors of antigenpresenting cells (APC) for antigen presentation including CD40, CD80 and CD86, HLA genes,
IgG immunoglobulin receptor (FcR) III and interferon-gamma (IFN-g) were upregulated in SARS-

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

CoV-2 ARIs compared to non-viral ARIs, whereas IgA and IgE FcRs, interferon-kappa (IFN-k),
and cyclooxygenase (COX) genes PTGS1 and ALOS5 were downregulated. The gene
expression of ACE2, CD80, CD86, CD83, IFN-g, FCER1G and IgG FcRs were increasingly
associated with the viral load of SARS-CoV-2 (Fig. 1A, Fig. S1). No such association were
observed in HLA genes. In addition, the proportions of activated CD4+ memory T cells (CD4m
T) and M1 MÃ¸ were increased in SARS-CoV-2 ARIs and significantly associated with increased
viral load (Fig. 1A, Fig. S1), while the proportions of activated mast cells and neutrophils were
decreased. The proportions of these 4 cell types and the active DC well predicted the SARSCoV-2 load (ğœŒ = 0.79, ğ‘ƒ = 1.3 Ã— 10!% , Fig. 1A) and discriminated between non-viral and SARSCoV-2 ARIs (ğ‘ƒ = 1.2 Ã— 10!& , Fig. S1).
Interestingly in ARIs with a significant SARS-CoV-2 viral load (log10 CPM > 1), we observed
distinct subtypes associated with activation of DCs and T/MÃ¸ cells (Fig. 1B). According to the
activation of specific immune cell types, we further classified ARIs into four subtypes DC+ and
T/MÃ¸+, Neu+ and DC-T/MÃ¸-Neu- (Fig. 1B). The DC+ subtype was characterized with activated
DCs, downregulated FcRs and HLA genes. The T/MÃ¸+ subtype was characterized with
activated T or MÃ¸, upregulated viral gateway ACE2 and CD209 as well as immune factors
including INFG, CD86, FCGR3A, FCGR1G and HLA genes. The Neu+ subtype was
characterized with enriched neutrophils, upregulated FcRs genes and Cox genes (PTGS2 and
ALOS5), and downregulated HLA genes and ACE2. The DC-T/MÃ¸-Neu- subtype was
characterized with downregulated FcRs genes, ACE2 and CD209. These results provide new
clues for the variation of immune response in COVID patients with its potential link to the
activation of specific immune cell types. Not like the T/MÃ¸+ subtype with activated immune
factors and high expression of ACE2 and CD209, DC+, Neu+ and DC-T/MÃ¸-Neu- subtypes may
produce high virus load by immunodeficiency.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

DC-SIGN is associated with COVID-19 severity, immune- and neural-related phenotypes
and respiratory diseases
We investigated the association of the expression of ACE2, DC-SIGN and L-SIGN with COVID19 risk by large-scale population genetic association analyses (see Methods). Using Mendelian
Randomization (MR), we found that the expression of DC-SIGN plasma protein were associated
with increased COVID-19 risk (ğ›½ = âˆ’0.14, ğ‘ƒ = 3.39 Ã— 10!' ) and severity (ğ›½ = âˆ’0.30, ğ‘ƒ =
5.41 Ã— 10!& ; Table S1). Such significant associations were not found in ACE2 and L-SIGN.
The important role of DC-SIGN in phagocytosis and immune activation was also reflected
by the phenotype associations detected in this study. GWAS found that the genetic variation of
CD209 is associated with multiple diseases, including asthma (the top among detected
associations, ğ‘ƒ = 1.0 Ã— 10!"' ), cancers and neurological disorders (Table S2), showing the
possible underlying links involving by DCs and/or MÃ¸. Neurological symptomatology associated
with COVID-19 includes headaches, confusion, hyposmia, encephalitis, myelitis, neuropathy,
and stroke19,20. Given circulating DCs in cerebrospinal fluid are capable of reaching cervical
lymph nodes outside central nervous system (CNS)21, our data suggests DCs is a possible
route for SARS-CoV-2 infection in the brain, which also provides a new explanation to the
neurotropism of SARS-CoV-222. Moreover, the transcriptome-based PheWAS analysis found
that CD209 gene expression is significantly associated with the immune cell composition,
including the depletion of neutrophils (count: ğ›½ = âˆ’0.10, ğ‘ƒ = 4.0 Ã— 10!& ; percentage: ğ›½ =
âˆ’0.60, ğ‘ƒ = 3.2 Ã— 10!& ) and overall WBC (count: ğ‘§ = âˆ’3.34, ğ‘ƒ = 8.3 Ã— 10!$ ), as well as the
augmentation of lymphocytes (percentage: ğ›½ = 0.14, ğ‘ƒ = 3.00 Ã— 10!$ ) and monocytes
(percentage: ğ›½ = 0.15, ğ‘ƒ = 1.24 Ã— 10!' ) in lung (Table S3). These associations were further
confirmed by MR analysis on DC-SIGN plasma protein expression (neutrophil count: ğ›½ =
âˆ’0.03, ğ‘ƒ = 1.38 Ã— 10!"( ; neutrophil percentage: ğ›½ = âˆ’0.02, ğ‘ƒ = 0.02; WBC count: ğ›½ =
âˆ’0.03, ğ‘ƒ = 5.40 Ã— 10!)% ; lymphocyte percentage: ğ›½ = 0.02, ğ‘ƒ = 5.29 Ã— 10!& ; monocyte

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

percentage: ğ›½ = 0.03, ğ‘ƒ = 8.52 Ã— 10!' ; Table S4). Moreover, we also observed such significant
associations of CD209 expression with immune cell composition in blood samples of 160 ARDS
cases and 142 non-ARDS controls, regardless of the disease status (Fig. S2). In addition, we
found that CD209 expression was associated with immune related symptoms such as tiredness
or low energy, depression and duration of fitness (Table S3). In lung adenocarcinoma tumors,
we only observed a slight downregulation of CD209 (ğ‘ğ‘’ğ‘¡ğ‘ = âˆ’0.26, ğ‘ƒ = 0.07) and no significant
association with survival (ğ‘ƒ = 0.33) and tumor stage (ğ‘ƒ = 0.80).

Smoking upregulates the expression and decreases the methylation of CD209 in lungs.
We previously have found that smoking upregulates the lung expression of ACE218. In this
study, we further investigated the effect of smoking on expression of CD209 and CLEC4M from
8 independent studies (N=1162). Adjusted for age and sex, CD209 expression was significantly
upregulated in smoker lungs (meta-analysis ğ›½ = 0.15, ğ‘ƒ = 1.1 Ã— 10!$ , Fig. 2A). Significant
association (meta-analysis ğ›½ = 0.1, ğ‘ƒ = 0.03) between CD209 expression and smoking status
(never-, former- and current- smoker) was also observed with 4 out of 5 available datasets
showing a positive trend of association (Fig. 2A). We did not find a significant difference in
CLEC4M gene expression (Fig. S3).
We next investigated the dysregulation of ACE2, CD209 and CLEC4M in specific types of
cells in normal airway samples of never-smokers and ever-smokers. Cell types were identified
from scRNA-seq datasets of bronchial epithelium (GSE131391) and lung tissues (GSE122960
and Madissoon) using known markers (Fig. S4, Fig. S5). We found that ACE2 was mainly
expressed in pneumocytes, secretory cells, ciliated cells, never-smokersâ€™ club cells and
smokersâ€™ goblet cells (Fig. 2B), which was consistent with the recent study of Ziegler et al.23 and
our pervious observation18. Compared to never-smokers, we found higher detection rate of
ACE2 in ciliated cells in ever-smokers in both lung datasets. The GSE122960 dataset also

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

showed higher expression of ACE2 in AT1 and fibroblast cells by smoking. Active expression of
CD209 was found in lung DCs, MÃ¸ and monocytes (Fig. 2B). Compared to non-smokers, eversmokers showed increased CD209 expression in lung DCs (GSE122960 P < 0.01 and
Madissoon P < 0.01). Higher CD209 expression was also found in MÃ¸ of ever-smokers in the
dataset of GSE122960 (P < 0.001). The expression of CLEC4M was only notably detected in
lung vessel epithelial cells and no significant smoking effect was observed.
Further, we investigated smoking effect on gene methylation of CD209 and ACE2 by
comparing DNA methylation data from smoker and non-smoker lungs in 5 studies (N = 242).
Adjusted by age and sex, an overall decrease of methylation was detected across CD209 in
smokers, including two significant loci (cg01618851, cg07608333) by meta-analysis and two
significant loci (cg04015765, cg21848746) in the GSE133062 study (Fig. 2C). Although not
significant with limited sample size, loci cg01618851 and cg07608333 showed trends of
negative correlation between CD209 gene expression and methylation (Fig. 2C). No data was
available to investigate the expression-methylation association for loci cg04015765 and
cg21848746. In addition, no significant association was observed in ACE2 (Fig. S6).

Smoking modulates the function of lung DCs
To verify whether smoking affects the composition of immune cells in lung, we assessed
immune cell proportions in normal lung tissues from the above 8 independent bulk
transcriptomics studies and evaluated their associations with smoking by meta-analysis. Among
22 immune cell types, we found that resting DCs, CD8+ T cells, and activated CD4m T cells
were augmented while resting CD4m T cells, activated NK cells, M1 MÃ¸, eosinophils and
neutrophils were depleted in lungs of smokers (Fig. 3A left). A similar pattern of associations
with smoking history (never, former or current smoker) was observed, with significant positive
correlation for CD8 T cells and follicular helper T cells, and negative correlation for CD4 memory
resting T cells, activated NK cells, eosinophils and neutrophils (Fig. 3A right). In addition, both

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

resting and activated DCs showed trends of positive association with the smoking history. A
trend of increase of DC proportion in smokers was also found in scRNA-seq datasets (Fig. S7).
Further, we investigated whether smoking affects the maturation of DCs by examining the
gene expression of the maturation marker CD83 and the T-cell stimulatory molecules CD86,
CD80 and CD40 in the GSE122960 and Madissoon scRNA-seq datasets (Fig. 3B). In DCs of
ever-smoker lungs, we found a significant downregulation of CD83 in both datasets. In the
Madissoon dataset, we also found significantly lowered expression of CD40 and CD80. These
observations indicate that smoking inhibits both maturation and T cell stimulation ability of DCs,
although CD86 was upregulated in the Madissoon dataset. Pathway analysis also showed that
smoking inhibited viral detection and DC maturation including signaling pathways of T cell
receptor, B cell receptor, Toll-like receptor (TLR) and RIG-I-like receptor (RLR), as well as
pathways involved in Vibrio cholerae and Escherichia coli infections (Fig. 3C). Interestingly,
smoker lung DCs also showed upregulated pathways which are involved in immune responses,
including antigen processing and presentation, cytokine-cytokine receptor interaction, asthma
(Fig. 3D), graft versus host disease and others. In addition, smoking inhibited DNA replication
(Fig. 3D), cell cycle, metabolism and DNA repair related pathways, and invoked detoxification
processes.

SARS-CoV-2 modulates the function of DCs and CD209 expression
We next systematically investigated the cell type-specific expression of CD209 in upper airway,
lower airway and peripheral blood by analyzing scRNA-seq datasets from one
nasopharynx/pharynx, one BALF and two PBMC (Lee et al., Wilk et al.) studies from COVID-19
patients and healthy controls. Cell types were identified in each dataset (Fig. S8), and the
detection rates and average expression of ACE2, CD209 and CLEC4M were compared
between groups (Fig. 4A). Compared to healthy controls, patients with mild and severe disease
showed higher detection rates of ACE2 in the nasopharynx/pharynx secretory, ciliated, and

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

pulmonary epithelial cells. No notable expression of CLEC4M was observed in any cell type in
any of the four datasets.
Notable expression of CD209 was found in DCs, airway MÃ¸ and blood monocytes (Fig. 4A).
Significantly, we found that CD209 expression in lung monocyte-derived macrophages (MoD
MÃ¸) and blood classical (CD16- or CD14+) monocytes was severity-dependently decreased in
COVID-19, while CD16+ monocytes showed a severity-dependent increase of CD209
expression in the dataset of Wilk et al. In DCs, CD209 expression was decreased in lungs but
increased in blood of COVID-19 cases, as compared to healthy controls. With a small number of
detected DCs (N = 12), the Lee PBMC dataset didnâ€™t detect such increase in severe COVID-19
cases. The discrepancy among anatomical sites were also found in the alteration of the DC
proportion among white blood cells (WBC) (Fig. 4B). In airway samples, the proportion of DCs
was increased in mild cases and decreased in severe cases. A decrease was also found in
severe cases in blood, but no notable change was observed in mild cases. Inversely to DCs, the
proportions of MoD MÃ¸ and monocytes were increased in severe cases in all three tissues.
These observations may indicate a site-specific impact of COVID-19 on the differentiation of
monocytes to DCs and MÃ¸.
We further identified transcriptome-wide differently expressed genes (DEGs) and signaling
pathways in DCs in COVID-19 lung and blood (Fig. 5). Compared to healthy controls, an
extensive transcriptomic change was found in lung, with expression of 184 DEGs (93 for mild;
91 for severe, Fig. 5A) changed more than 2-fold, whereas only 15 (8 for mild; 11 for severe,
Fig. 5B) were detected in blood. Relatedly, we also found a broad COVID-19 severityassociated activation of viral detection and immune stimulation (cytokine-cytokine receptor
interaction, cytosolic DNA sensing, TLR, Nod-like receptor (NLR), chemokine signaling, B cell
receptor signaling and Mark signaling) in lung, while only mild immune stimulation (cytokinecytokine receptor interaction and cytosolic DNA sensing) was found in blood. In both lung and
blood, immune response related pathways (graft versus host disease, viral myocarditis,

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Leishmania infection and others) were activated in mild cases as compared to healthy control
but interestingly were inhibited in severe cases as compared to mild cases. Such pattern was
also observed on antigen processing and presentation, host metabolism as well as DNA
replication in lung but not in blood. Correspondingly, immune initiation related genes (including
CD1A, CD1C, CD1E, CCL17, FCER1A, FCGR2B and others) and ribosome genes were
significantly downregulated in severe COVID-19 cases as compared to healthy controls,
whereas inflammatory signals (including interferon genes, CCL2, CCL4, CCL8 and others) were
upregulated (Fig. 5C). Compared to mild cases, chemokines (including CCL2, CCL4, CCL8)
and MAPK substrates (including JUN, USF1, FOS) were upregulated in severe cases, whereas
antigen presentation related genes (HLA-DQA2, C1QC and C1QA) were downregulated.
Interestingly in blood, we also found neural disease related pathways were severity-dependently
activated and cancer related pathways were inhibited in severe cases (Fig. 5B), which may link
to the neurologic and other clinical manifestations of COVID-19.
The expression of the maturation marker (CD83), T-cell stimulation molecules (CD40,
CD80, CD86) and antigen presentation molecules (HLA-DQA2 and FCER1A) showed the
dysregulation of DC function in COVID-19 (Fig. 6A). In lung, CD40, CD80, CD83 and HLADQA2 were upregulated while CD86 and FCER1A were decreased in mild COVID-19 as
compared to healthy controls. Similar patterns were observed on CD40, CD86 and HLA-DQA2
in both blood datasets while inconsistent results of CD83 and FCER1A were observed in Lee
and Wilk PBMC datasets. Compare to mild cases, severe COVID-19 showed upregulated CD40
as well as downregulated CD83, HLA-DQA2 and FCER1A in all three tissues. Interestingly,
asymptomatic cases showed similar expression of those markers with healthy controls in blood.
In addition, we investigated the expression of MHC class II molecules (MHCII) and Fc
receptors (FcRs) and found that they were broadly activated in APCs in lungs of mild COVID-19
patients, with a MHCII subset (HLA-DRA, HLA-DMB, HLA-DRB1, HLA-DPB1, HLA-DQB1, HLADMA) were downregulated (Fig. 6B). Compared to mild cases, severe cases showed decreased

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

MHCII expression in airway APCs but not significantly in blood. The result was in agreement
with above pathway analysis that antigen processing and presentation were activated in mild
cases but inhibited specifically in lungs of severe cases. Significantly in lung and blood APCs,
HLA-DQA2 expression were increased in mild cases as compared to healthy controls but
downregulated in severe cases as compared to mild cases. Interestingly, compared to healthy
controls, the global change of MHCII and FcRs gene expression in blood were associated with
COVID-19 severity, with upregulation in asymptomatic cases, no significant change in mild
cases and downregulation in severe cases (Fig. S9).
Together, these observations indicate the ability of DCs for T-cell stimulation is induced but
the maturation of DCs is inhibited in both lung and blood of severe COVID-19, and specifically
the antigen presentation ability of APCs is reduced in lung, which is the primary site of infection.

Conventional DC subsets were depleted and new immature DC subsets were
accumulated in severe COVID-19
We further investigated the variation of DC subsets in nasopharynx/pharynx, BALF and PBMC
samples from COVID-19 patients and healthy controls. Based on known markers (Fig. S10),
four DC subsets were identified in the nasopharynx/pharynx samples, including type I and II
conventional dendritic cells (cDC1 and cDC2), MÃ¸-like DC which expressed MÃ¸ markers
S100A8 and S100A9, Plasmacytoid dendritic cell (pDC) and a new subset of CD22+ITM2C+ DC;
seven subsets were identified in the BALF samples, including cDC1, cDC2, mature cDC2, MÃ¸like DC, pDC and new subsets CD22+ DC and ANXA1+ DC; four subsets were identified in the
PBMC samples from the Lee dataset, including cDC1, cDC2, mature cDC2 and MÃ¸-like DC;
four subsets were identified in the PBMC samples from the Wilk dataset, including cDC1, cDC2,
mature cDC2 and MÃ¸-like DC (Fig. 7A). The integration of all datasets found that these subsets
were conservative among tissues (Fig. S11). CD22+ITM2C+ DC in nasopharynx/pharynx
samples were clustered together with CD22+ DC in BALF samples, which were characterized by

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

the activated immune response (ğ‘ = 1.17 Ã— 10!& ) and interferon gamma response (ğ‘ =
1.17 Ã— 10!& ).
Among DCs, the proportion of cDC2 was severity-dependently decreased in both lung and
blood of COVID-19 (Fig. 7B). Inversely, the mature cDC2 was increasingly correlated with
disease severity in lung BALF samples. Such increase was also found in PBMC with mild
COVID-19 but not in severe cases which might be due to its limited cell detection of DC cells
(N=12). pDC showed a notable augmentation in BALF and depletion in PBMC in mild cases but
not in severe cases, which may reflect the different migration activeness of pDC from blood to
lung in mild and severe COVID-19. Interestingly, all tissues in severe cases showed
augmentation of immature DC subsets with decreased mature markers CD83, T-cell stimulation
activators (CD40, CD80, CD86) and HLA genes, including CD22+ITM2C+ DC and MÃ¸-like DC in
nasopharynx/pharynx samples, ANXA1+ DC and pDC in BALF samples, MÃ¸-like DC and pDC in
PBMC samples. Indeed, in nasopharynx/pharynx samples, the proportion of CD22+ITM2C+ DC
was significantly positively correlated with that of M0 MÃ¸ (ğ‘ƒ = 8.6 Ã— 10!& ), resting CD4 memory
T cells (ğ‘ƒ = 0.028) and resting mast cells (ğ‘ƒ = 0.024) (Fig. S12). In addition, we found the BALF
specific ANXA1+ DC subset showed high expression of COX related genes PTGS1, PTGS2,
HPGDS, ALOX5 and LTC4S, which may be responsible for the DC immunity suppression24,
together with ANXA125.
We observed a clear shift from conventional DCs to pDC on single cell trajectory in COVID19 BALF and PBMC, in response to viral infection (Fig. 7C). However, the shift was trapped in
the path in severe cases, producing immature subsets. The blockade was also observed in
nasopharynx/pharynx with severe COVID-19 (Fig. S13). Further we found that both bursting
frequency and size of MCHII genes were inhibited in the lung specific immature subset ANXA1+
DC as compared to cDC2 and pDC (Fig. S14). Increased frequency and size of Cox genes were
also observed. This indicate the SARS-CoV-2 infection may inhibit the DC maturation by

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

regulating the expression kinetics parameters (bursting frequency and bursting size) of related
genes.

Discussion
ACE2, DC-SIGN and L-SIGN are three receptors of both SARS-CoV and SARS-CoV-2. No data
is available to indicate they are dependent viral entry portals and we did not find significant
correlations of the gene expression between ACE2 and that of DC-SIGN and L-SIGN (Fig. S15).
Given that DC-SIGN is mainly expressed on the surface of DCs and MÃ¸, the viral infection to
immune cells may directly link to the immunopathogenesis and disease severity of COVD-19.
Indeed, we found higher gene expression of ACE2 and CD209 in upper airway cells of COVID19 ARIs compared to non-viral ARIs, and CD209 plasma protein expression was correlated
COVID-19 risk and severity. We also observed their association with the variation of immune
cell activation in upper airway cells of COVID-19 ARIs that high expression was only found in
the T/MÃ¸ activated cells. This might be a result from the immune stimulation by intensive viral
attack to ACE2 and DC-SIGN expressing cells. This may also reflect the negative correlation of
CD209 expression with neutrophil percentage and the positive correlation with T cell
percentage, which were detected by our large-scale population genetic association study.
Indeed, the activated neutrophils produce TNF-alpha and induce DC maturation which lower the
CD209 expression26; CD209 mediates the activation of T cells27. The neutrophil-to-lymphocyte
ratio has been studied as a severity marker in COVID-1928 and as a valid prognostic factor in
various solid tumors and other chronic diseases29. Therefore, the interaction of CD209 and DCs
with neutrophils and T cells may play an important role in mediating cytokine storm coupled with
limited anti-viral capability, which are keys in COVID-19 pathogenesis30. Further investigation is
required to elucidate this interaction and the causal effect of ACE2 or CD209 to the COVID-19
risk.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

For the first time, we performed a systematic investigation of the expression of SARS-CoV2 receptors in single cells of upper airway, lower airway and blood of COVID-19 patients. We
found CD209 expression and the percentage of DCs and MoD MÃ¸ or monocytes were
associated with COVID-19 severity. Interestingly, the associations were site specific. In the lung
and upper airway with mild infection, DCs were induced for an active immune response and an
cell augmentation. In the cases of severe infection, the decrease of DCs proportion and
maturation could be a sign exhaustion of DCs. Also, the decreased expression of CD209 in DCs
of COVID-19 lungs may be a result of cell death caused by direct viral infection. Differently,
blood showed induced DC activation and increased CD209 expression, which may indicate that
DCs are stimulated in blood but not attacked by virus. Indeed, no SARS-CoV-2 sequencing
reads were detected from COVID-19 PMBC16. Interestingly, DCs in lungs of severe COVID-19
showed upregulation of T cell stimulation but downregulation of antigen presentation and
maturation, indicating that DCs may stimulate innate immune system but fail to recognize
SARS-CoV-2. This may lead to the negatively correlated cytotoxic follicular helper response
with antibody levels to SARS-CoV-2 spike protein in hospitalized COVID-19 patients31. SARSCoV-2 might use an escape mechanism similar to HIV-1 which hides in DCs and uses DC-SIGN
as a trans-receptor for efficient transmission to T cells, and also similar to Mycobacteria
tuberculosis (M. tb) which subverts DCs by targeting DC-SIGN and inhibiting maturation32. The
stimulated and â€œblindedâ€ immune systems could be responsible for the cytokine storm as well as
severe ARDS suffering COVID-19 critical cases. MHCII genes especially HLA-DQA2 might be
involved in this pathogenesis, which were found to be decreased in lung of severe cases
compared to mild cases. This may also link to the olfactory impairment which is often seen in
patients with COVID-19, given that MHC are essential in individual olfactory perception33.
The observed broad downregulation of MHCII genes in APCs was aligned with recent
findings that dysfunctional monocytes34,35 and B cells36 in severe COVID-19. Here, we report a
shift from cDCs to pDCs in COVID-19 cases, which leads to the marked disease severity-

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

dependent depletion of cDC2 in all studied tissues. Strikingly, the shift was blocked in immature
subsets including CD22+ DC and ANXA1+ DC with suppressed activation markers. This
immunosuppression of DCs may contribute to the variation of disease severity through the
interactions between DCs and T cells and other immune cells. Indeed, we found the immature
subtype CD22+ITM2C+ DC was significantly positively correlated with the resting subsets of MÃ¸,
CD4mT and mast cells in upper airway.
In this study, we also investigated the smoking effect on respiratory gene expression of
these three receptors of both SARS-CoV and SARS-CoV-2. We found ever-smokers had
significantly higher ACE2 and CD209 gene expression than non-smokers, respectively in lung
AT1 cells and monocytes/DCs. Our results indicate that this smoking effect might be mediated
by methylation regulation. Indeed, methylation switch CD209 genes during the differentiation of
human Monocytes to dendritic cells37. Also, DCs maturation and signaling pathways such as
TLR signaling for viral detection and innate immune initiation were inhibited by smoking. Thus,
smoking may accomplice the escape of SARS-CoV-2 from immune surveillance by targeting
DCs, as shown in this study that antigen presentation and maturation are inhibited in DCs in
severe COVID-19 lungs. Indeed, cigarette smoking has been confirmed to increase the
susceptibility to various respiratory diseases such as pneumococcal disease and
pneumonia38,39. Severance et al. also identified smoking status as a risk factor for the exposure
of four non-SARS coronavirus strains among US population40. Interestingly, we also found
smoking induces the DC proportion and enhances immune responses related pathways in DCs.
These results indicate that DCs from smoking individuals have lower ability to stimulate T cells
to attack a pathogen but actively induce immune responses and release cytokines, which may
partially contribute to the cytokine storm in severe COVID-19 patients. Together with the
upregulation of ACE2 and CD209 expression by smoking, this may explain the clinical
presentation of 1,099 cases of COVID-19 that the smokers had a higher risk of severe
disease41.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Collectively, this study provides important pieces of puzzle of COVID-19 about
dysfunctional DC cells from the expression of receptors of SARS coronavirus, the effect and
potential risk of smoking, and remodeling of DC activation and redistribution of DC subsets.
Although further studies with a larger sample size of single cell or single cell type studies will be
needed to properly assess this matter, this study provide important hints for vaccine
development, as well as the variation of COVID-19 severity and pathogenesis.

STARâ˜…Methods
Key Resources Table
REAGENT or RESOURCE
Deposited Data
TCGA bulk RNA-seq transcriptome data
of normal lung tissues from patients
with lung cancer adenocarcinoma
GSE40419 bulk RNA-seq transcriptome
data of normal lung tissues from
patients with lung cancer
adenocarcinoma
GSE10072 bulk microarray
transcriptome data of normal lung
tissues from patients with lung cancer
adenocarcinoma
GSE63127 bulk microarray
transcriptome datasets of healthy small
airway epithelium
GSE19667 bulk microarray
transcriptome datasets of healthy small
airway epithelium
GSE5058 bulk microarray transcriptome
datasets of healthy small airway
epithelium
GSE7895 bulk microarray transcriptome
datasets of healthy large airway
epithelium
mNGS data of nasopharynx/pharynx
samples from ARIs with or without
COVID-19
GSE131391 scRNA-seq data of
bronchial epithelial cells from eversmokers and non-smokers

SOURCE

IDENTIFIER

Firehose
https://gdac.broadinst
itute.org/

Level 3, version
2016_07_15

GEO

GSE40419

GEO

GSE10072

GEO

GSE63127

GEO

GSE19667

GEO

GSE5058

GEO

GSE7895

42

https://github.com/czbiohub/C
OVID-19-transcriptomicspathogenesis-diagnosticsresults

GEO

GSE131391

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

GSE122960 scRNA-seq data of normal
lung tissues from ever-smokers and
non-smokers
Madissoon scRNA-seq data of normal
lung tissues from ever-smokers and
non-smokers
scRNA-seq datasets of
nasopharynx/pharynx samples from
COVID-19 patients and healthy controls
scRNA-seq datasets of BALF samples
from COVID-19 patients and healthy
controls
scRNA-seq datasets of Lee PBMC
samples from COVID-19 patients and
healthy controls
scRNA-seq datasets of Wilk PBMC
samples from COVID-19 patients and
healthy controls
TCGA bulk methylation data of normal
lung tissues from patients with lung
cancer adenocarcinoma
GSE32861 bulk methylation data of
normal BALF samples
GSE133062 bulk methylation data of
normal BALF s
GSE92511 bulk methylation data of
normal lung samples
GSE139032 bulk methylation data of
normal lung samples
GSE32863 bulk microarray
transcriptome data of normal lung
samples
Plasma protein QTL summary statistics

GEO

GSE122960

NCBI BIOPROJECT

PRJEB31843

43

https://doi.org/10.6084/m9.
figshare.12436517

GEO

GSE145926

GEO

GSE149689

44

https://www.COVID19cellatlas.org/#wilk20

TCGA

v25

GEO

GSE32861

GEO

GSE133062

GEO

GSE92511

GEO

GSE139032

GEO

GSE32863

45

COVID-19 risk GWAS summary
statistics

NIH GRASP

COVID-19 severity GWAS summary
statistics
Processed scRNA-seq data of DCs

NIH GRASP

http://www.phpc.cam.ac.uk
/ceu/proteins/
files with name
â€œALLwhitesâ€ at 06-052020) for COVID-19 risk
study of Ellinghaus et al.46

Supplemental Table S1, Table
S2, Table S3, Table S4
Software and Algorithms
R

This paper
https://www.cran.rproject.org

v4.0.2

RMA
edgeR
CIBERSORT

Bioconductor
Bioconductor

affy v3.11
v3.30.3
https://cibersort.stanford.e
du/

This paper

47

https://thecailab.com/SCA
NNER
https://data.mendeley.com/
datasets/bjzfxw4jrf/1

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

MuSiC

GitHub

STAR

GitHub

FastQC

MultiQC

http://www.bioinforma
tics.babraham.ac.uk/
projects/fastqc
http://qualimap.cones
alab.org/
GitHub

bcbioRNAseq
limma-voom
Seurat

Bioconductor
Bioconductor
GitHub

Monocle
GSEAPreranked

Bioconductor
GenePattern,
https://www.genepatt
ern.org/#
https://cytoscape.org/
http://apps.cytoscape
.org/apps/stringapp
http://www.phenosca
nner.medschl.cam.ac
.uk/
http://apps.hakyimlab
.org/phenomexcan/
GitHub

Qualimap

Cytoscape
StringAPP
PhenoScanncer
PhenomeXcan
TwoSampleMR
Rstan
SCANNER

CRAN
48

https://github.com/xuranw/
MuSiC
v2.7
https://github.com/alexdobi
n/STAR
v0.11.9
V2.2.1
https://github.com/ewels/M
ultiQC
v0.2.9
v3.44.3
v3.0
https://github.com/satijalab
/seurat
v2.16.0
v1
v3.8.1
v1.6.0
v2
February 28, 2020
https://github.com/MRCIE
U/TwoSampleMR
v2.21.2
https://thecailab.com/SCA
NNER

Bulk transcriptomics
Normal lung and airway samples from ever-smokers and non-smokers
We used eight datasets (N = 1162) to investigate the gene expression of three SARS
coronavirus receptors (ACE2, DC-SIGN and L-SIGN, with gene symbols ACE2, CD209 and
CLEC4M) in bulk tissues, including four datasets of normal lung tissues from patients with lung
cancer adenocarcinoma (TCGA RNA-seq dataset (N = 48)49, Institut universitaire de cardiologie
et de pneumologie de QuÃ©bec (IUCPQ) microarray dataset50 (N = 475), Gene Expression

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Omnibus (GEO) GSE40419 RNA-seq dataset51 (N = 74) and GSE10072 microarray dataset52
(N = 33)), three microarray datasets of healthy small airway epithelium (SAE) samples
(GSE6312753 (N = 230), GSE1966754 (N = 116) and GSE505855 (N = 24)) and a microarray
dataset of healthy large airway epithelium (LAE) samples from GSE789556 (N = 104). We
studied the Reads Per Kilobase per Million mapped reads (RPKM) values for RNA-seq data and
Robust Multi-array Average (RMA)57 values for microarray data. All data were log2 transformed
to improve normality. Never-smokers and ever-smokers (including current and former smokers)
were identified in each original study based on self-reported smoking history. Multivariate linear
regressions were used to test the association of ACE2, CD209 and CLEC4M gene expression
with smoking status adjusted for age and sex. Meta-analysis was performed by pooling effect
size and standard error estimated from each study using a random effects model with HunterSchmidt estimator.

Upper airway samples from patients with or without COVID-19
We studied the metagenomic next generation sequencing (mNGS) data of
nasopharynx/pharynx samples from 197 patients with acute respiratory illnesses, including 94
patients confirmed with SARS-CoV-2 infection by clinical PCR and 103 with no virus detected42.
The host gene expression read counts and the CPM (read counts for million) of SARS-CoV-2
virus were analyzed. We normalized the read counts of ACE2 and CD209 using the TMM
method and calculated CPM using edgeR58. The data for CLEC4M was not available.
We deconvoluted the immune cell composition from these bulk RNA-seq data using
CIBERSORT47 with its signature matrix, LM22. In each sample, the proportions of 22 human
hematopoietic cell types were inferred, including naÃ¯ve and memory B cells, plasma cells, 7 T
cell types (CD8, CD4 native, memory resting CD4, memory activated CD4, follicular helper,
regulatory (Tregs) and gamma delta), NK cells (resting and activated), monocytes,
macrophages (M0, M1 and M2), dendritic cells (resting and activated), mast cells (resting and

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

activated), eosinophils and neutrophils. Using transcriptome profiles of DC subsets identified in
below scRNA-seq datasets of nasopharynx/pharynx samples, we also estimated the
composition of DC subsets in these bulk RNA-seq data using MuSiC59.
Linear regression was used to test the difference of gene expression or immune cell
proportions between sample groups as well as their association with SARS-CoV-2 viral load in
samples.

Blood samples from ARDS cases and controls
From the Molecular Epidemiology of ARDS (MEARDS) prospective cohort study60,160 Acute
Respiratory Distress Syndrome (ARDS) cases and 142 controls were recruited for RNA-Seq
analysis of blood samples. RNA was extracted by PAXgene Blood RNA Kit (QIAGEN) and
selected by using oligo(dT) beads. Sequencing libraries were built using MGIEasy RNA Library
Prep Kit and subsequently sequenced on the MGISEQ-2000 platform. The 100 bp pair-end
sequencing reads were filtered to remove low-quality, adaptor-polluted and high content of
unknown base (N) reads. Further, sequencing reads were mapped to reference genome
GRCh38 using STAR61 and counts of reads aligning to known genes were generated by
featureCounts62. Quality controls were performed for evenness of coverage, rRNA content,
genomic context of alignments using FastQC
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc), Qualimap63, MultiQC
(https://github.com/ewels/MultiQC), and bcbioRNAseq (version 0.2.9)64. Then, limma-voom65
was used to perform whole-transcriptome differential expression analysis from raw counts.

Single-cell transcriptomics
Normal airway samples from ever-smokers and non-smokers
We analyzed three single-cell RNA sequencing datasets including GSE13139166, GSE12296067
and a dataset from Madissoon et al.68. The GSE131391 dataset focused on bronchial epithelial

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

cells, ALCAM+ epithelial cells and CD45+ white blood cells from 6 never- and 6 currentsmokers. The GSE122960 dataset was from lung tissues of 8 lung transplant donors, including
5 never- and 3 ever-smokers. The Madissoon dataset was from lung tissues of 4 never- and 3
ever-smokers. Sequencing read counts in single cells were downloaded, and subsequent data
analyses were performed using the Seurat 3.0 package69, including data normalization, high
variable feature selection, data scaling, dimension reduction and cluster identification. The
Louvain method was used on the top 20 principle components to identify clusters, which were
visualized in reduced dimensions of Uniform Manifold Approximation and Projection (UMAP).
Cell types were assigned to clusters based on markers used in each original study. In
GSE131391 samples, we identified club cells, goblet cells, ciliated cells, CD45+ white blood
cells (WBC), ionocytes, basal cells and a basal cell sub-population (basal-2) which was shown
in smokers. In GSE122960 samples, we identified alveolar type I cells (AT1), alveolar type II
cells (AT2), macrophages, monocytes, endothelial cells, ciliated cells, club cells, B cells, T/NKT
cells, DCs and fibroblast cells. In samples from the study of Madissoon et al., we identified AT1,
AT2, macrophages, monocytes, ciliated cells, B cells, T cells, NKT cells, DCs, mast cells,
fibroblast cells, muscle cells, plasma cells, blood vessel endothelial cells (VesselEpi-b) and
lymph vessel endothelial cells (VesselEpi-l).

Upper airway, lower airway and peripheral blood samples from COVID-19 patients and healthy
controls
We investigated the gene expression of ACE2, CD209 and CLEC4M in scRNA-seq datasets of
nasopharynx/pharynx, BALF and PBMC samples from COVID-19 patients and healthy controls.
The nasopharynx/pharynx data were available in the study of Chua et al.43 with the count matrix
and cell type identification derived from 11 moderate and 8 critical COVID-19 patients and 5
healthy controls. We also downloaded the count data of BALF samples from 6 severe and 3
mild COVID-19 patients as well as 3 healthy controls from GEO GSE14592615. Also, the count

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

data from PBMC samples of 6 severe, 4 mild, and 1 asymptomatic COVID-19 patients and 4
healthy controls were downloaded from GEO GSE149689 of Lee et al.70. In addition, we
analyzed another PBMC scRNA-seq dataset from the study of Wilk et al.44, which was from 6
healthy controls and 7 COVID-19 patients. 4 of 8 COVID-19 samples were collected from
patients who were diagnosed with ARDS and were ventilated. Two samples were collected from
one patient in the non-severe condition without ventilation and in the severe condition with
ventilation.
scRNA-seq data processing was performed using Seurat with steps same as above.
110145 cells including 9326 DCs were analyzed in the nasopharynx/pharynx dataset. 71415
cells including 1484 DCs were analyzed in the BALF dataset. 58187 cells including 526 DCs
were analyzed in the Lee et al. PBMC dataset. 36925 cells including 514 DCs were analyzed in
the Wilk PBMC dataset. Cell types in the nasopharynx/pharynx dataset and the Wilk et al.
PBMC dataset were identified by their original studies. Following the approaches used in the
study of Wilk et al.44, we used SingleR71 and markers used in each original study, we identified
cell types for cell clusters detected in the BALF and Lee et al. PBMC datasets. In the
nasopharynx/pharynx samples, we identified squamous cells, non-resident macrophages (NR
macrophages), monocyte-derived macrophages (MoD macrophages), resident macrophages (R
macrophages), neutrophils, CD4+ T cells, CD8+ T cells, B cells, ciliated cells, NK cells, NKT
cells, Diff ciliated, DCs, IFNG-responsive cells (IRC), basal, secretory, differentiating secretory
(Diff secretory), outliers epithelial cells (Out epithelial), ionocytes, Unknown epithelial cells, mast
cells and FOXN4+ cells. In the BALF samples, we identified CD8+ T cells, CD4+ memory T cells
(CD4m T), gamma delta T cells (gd T), alveolar macrophages (A macrophages), MoD
macrophages, epithelial cells, DCs, NK cells, plasma B cells (PB), neutrophils and monocytes.
In the Lee PBMC dataset, we identified immature B cells, naive B cells, CD4m T cells, CD8+ T
cells, CD4+ T cells, erythroblasts, gd T cells, CD16+ monocytes, CD16- monocytes, platelets, NK
cells, DCs and intermediate monocytes (Int monocytes). In the Wilk PBMC dataset, we

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

identified activated granulocytes (Act granulocytes), B cells, CD14+ monocytes, CD16+
monocytes, CD4+ T cells, CD4m T cells, naive CD4+ T cells (CD4n T), effector CD8+ T cells
(CD8eff T), CD8m T cells, class-switched B cells (Switched B), DCs, gd T cells, IgA-producing
PB cells (IgA PB), IgG-producing PB cells (IgG PB), neutrophils, NK cells, DCs, platelets, red
blood cells (RBC), as well as stem cells and eosinophils (SC & Eosinophil). To compare gene
expression in groups, Wilcoxon rank sum test was used.
To identify DC subsets, we used well evidenced markers for cDC1 (CLEC9A, C1orf54,
HLA-DPA1, CADM1, CAMK2D, XCR1), cDC2 (CD1C, FCER1A, CLEC10A), pDC (DAB2,
GZMB, JCHAIN, SERPINF1, ITM2C, CLEC4C, LILRA4), mature DC (LAMP3, CD86, CD83,
CD40, ICAM1, ITGA4, CCL8, CCL22, CCL17, CXCL8, CXCL9, CXCL10, CXCL11, CCR7),
macrophage-like DC (S100A9, S100A9, S100A8, VCAN, LYZ, CD14), AXL+ DC (ANXA1, AXL,
PPP1R14A, SIGLEC6, CD22) and non-classical DC (FCGR3A, CX3CR1). To evaluate the
similarity of DC subtypes identified in above scRNA-seq datasets, we integrated these datasets
using Seurat and visualized the integrated matrix with UMAP. Monocle72 was used to infer the
single cell trajectory.

Methylation analysis of CD209 and ACE2
In this study, five datasets (N = 237) of normal lung tissues were used to investigate the
association of smoking and DNA methylation of CD209, including two datasets of normal lung
tissues from patients of lung adenocarcinoma from TCGA49 (Illumina 450K BeadChip, N = 55)
and GSE3286173 (Illumina 27K BeadChip, N = 59), one dataset of BALF cells from
GSE13306274 (Illumina MethylationEPIC BeadChip, N = 35), and two datasets of normal nonmalignant lung samples from GSE9251175 (Illumina 450K BeadChip, N = 16) and GSE13903276
(Illumina 27K BeadChip, N = 77). Smoking history was determined by self-reported history.
Multivariate linear regressions were used to test the association of the M-values of CD209
methylation probes with smoking status adjusted for sex and age. Using the effect size and

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

standard error estimates from each study, a random-effects meta-analysis was performed as
described before. With paired data from the GSE3286373 mRNA expression and the GSE32861
methylation measurements, we also evaluated the correlation of CD209 expression abundance
and methylation level in 58 paired samples.

Group comparison and association testing
Linear regression was used to evaluate the association between variables and perform twogroup comparison. To evaluate the association of CD209 expression with tumor stage and
survival of lung adenocarcinoma tumors, ordinal regression and Cox proportional hazard model
were used respectively.

Pathway and network analyses
Pathway and network analyses were performed to systematically investigate biological
processes involved in smoking or COVID-19. We calculated transcriptome-wide fold changes
(FC) of expression and ranked the differential expression according to log2FC. For Based on
these ranks, preranked Gene Set Enrichment Analysis (GSEA)77 was applied to evaluate the
enrichment of Kyoto Encyclopedia of Genes and Genomes (KEGG)78 pathways. Further, the
summary statistics of GSEA analysis were used to build connection networks of detected
pathways by the Enrichment Map implemented in Cytoscape79. Pathways with Q-value<0.2
were included into networks and the connectivity strength was determined by an edge cutoff as
0.25. In addition, networks of genes with absolute value of the average of log2FC >1 were
constructed using the Cytoscape StringAPP80.

Inference and comparison of transcriptional bursting kinetics between DC subsets
To infer the bursting kinetics from single cell transcriptomic data, we developed a Bayesian
hierarchical framework to estimate the bursting kinetic parameters (i.e. transcribe rate ğ‘  ,

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

activation rate ğ‘˜*+ and deactivation rate ğ‘˜*,, ). In the spirit of the conventional Poisson-Beta
model (Vu et al., 2016), our method considered the transcriptional bursting process characterized
by burst size ğ‘ /ğ‘˜*,, and burst frequency ğ‘˜*+ . A major limitation of Poisson-Beta model is that it
neglects the remarkable noisy nature of sequencing technology81-83, which usually leads to
overestimation of the dispersion and consequently jeopardize the validity to infer bursting kinetics.
To address this issue, we reconstructed the mean-variance relationship by utilizing the
Generalized additive model (GAM) that can resist and down-weight the effect of a small number
of atypically high dispersion estimates especially for genes with few counts. The re-estimated
dispersion ğµğ¶ğ‘‰ based on the re-fitted mean-variance function was then incorporated into the
framework, assuming that the sampling distribution of the underlying mean ğœ† is gamma.
Specifically, let ğ‘¦ âˆ¼ ğ‘ƒğ‘œğ‘–ğ‘ ğ‘ ğ‘œğ‘›(Î») denotes the observed number of mRNA molecules,
Î» âˆ¼ ğ‘”ğ‘ğ‘šğ‘šğ‘(1/ğµğ¶ğ‘‰ .) , ğ‘ ğ‘ğµğ¶ğ‘‰ .) )
ğ‘|ğ‘˜*+ , ğ‘˜*,, âˆ¼ ğµğ‘’ğ‘¡ğ‘(ğ‘˜*+ , ğ‘˜*,, )
Where p denotes the fraction of time that a gene spends in the active state. With the proper
choices of the priors and hyperpriors, the posterior parameters were estimated via Markov Chain
Monte Carlo (MCMC) algorithm implemented in Rstan84.
We also formulated a differential bursting analysis framework that can further explored the
change in bursting kinetics between different study conditions. After applying the MCMC method,
the MCMC samples provided various representative combinations of bursting frequency and size
values, while the credible differences of bursting frequency and size could be examined by
computing and summarizing the changes at each combination of parameters values. Those
credible differences could then be used to assess the credibility of â€œnull valueâ€85.
We applied the proposed method to investigate the differences of bursting kinetics in ANXA1+
DCs in COVID-19 lung compared to pDCs and cDC2s separately. With the processed scRNA-

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

seq count data generated from previous pipeline, changes in bursting frequency and size
estimates (in log2 scale) were computed.

Transcriptome-based phenome-wide association study
We utilized public resources to search for CD209 related traits/disease candidate.
PhenoScanncer86 was used to obtain associated phenotypes from genome-wide association
study (GWAS) studies. Also, PhenomeXcan87 underlying phenome-wide association study
(PheWAS) analytic framework was used to infer associations of CD209 lung expression and
multiple traits, by integrating GWAS summary statistics of 4,091 traits and Genotype-Tissue
Expression data from GTEx88 lung tissue version 8.

Mendelian Randomization analysis
Mendelian Randomization (MR) analysis provides evidence for a causal relationship between
exposure and outcome. To infer the causal effect of plasma expression of ACE2 and DC-SIGN
on COVID-19 risk and severity, we applied the TwoSampleMR R package89 for MR analysis.
For exposures of protein expression of SARS-CoV-2 receptors, we obtained publicly available
plasma protein QTL summary statistics from the study of Sun et al.45. For outcomes of COVID19 risk and severity, we separately required GWAS summary statistics from GRASP
(https://grasp.nhlbi.nih.gov/COVID-19GWASResults.aspx; files with name â€œALLwhitesâ€ at 06-052020) for COVID-19 risk, and that from the study of Ellinghaus et al.46 for COVID-19 severity.
Independent genetic instruments of exposures were selected for MR analysis based on strict
criteria of minor allele frequency (MAF) > 0.05, linkage disequilibrium (LD) r2 < 0.01 within a
clumping window of 10,000 kb, and beyond genome-wide significance (P < 5Ã—10-8). As there
were no genetic instruments of plasma ACE2, the significance threshold for selecting
instruments was set as P < 10-4. Ultimately, we found 3, 60, and 1 SNPs as independent genetic
instruments for plasma CD209, ACE2, and CLEC4M, respectively. Inverse-variance-weighted

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

(IVW), weighted median, and MR-Egger regression methods were used to calculate effect size
(ğ›½) and corresponding standard error (SE). The Wald ratio method was used if only one genetic
instrument remained. Heterogeneity was estimated using MR-Egger and IVW methods.
Directional pleiotropy was estimated via MR-Egger intercept test.

Software
All data management, statistical analyses and visualizations were accomplished using R
software version 4.0.2.

Data availability
The data derived from MEARDS was accessible upon request to Dr. David C. Christiani
(dchris@hsph.harvard.edu). Data from other studies were openly available to the public without
registration or application for access. Processed single cell transcriptomics data were available
for visualization and exploration in SCANNER48 (https://www.thecailab.com/scanner/). The
hosted data include three datasets from the normal airway samples from ever-smokers and
non-smokers, as well as four datasets from the DCs of nasopharynx/pharynx, BULF and PBMC
samples from COVID-19 patients and healthy people.

Ethical oversight
All the data were de-identified and study approval has been stated in original studies. The
MEARDS study was reviewed and approved by institutional review boards of Massachusetts
General Hospital (MGH) and Harvard School of Public Health (project approval number:
1999P0086071/MGH).

Reference

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

1. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus
indicating person-to-person transmission: a study of a family cluster. Lancet 2020:S0140-6736(20)30154-9.
2. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol
2015;1282:1-23.
3. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat
origin. Nature 2020:10.1038/s41586-020-2012-7.
4. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis
based on decade-long structural studies of SARS. J Virol 2020:JVI.00127-20.
5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet 2020:S0140-6736(20)30183-5.
6. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS
coronavirus. Nature 2003;426:450-4.
7. Yang Z-Y, Huang Y, Ganesh L, et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is
mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 2004;78:564250.
8. Jeffers SA, Tusell SM, Gillim-Ross L, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome
coronavirus. Proc Natl Acad Sci U S A 2004;101:15748-53.
9. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat
origin. Nature 2020;579:270-3.
10. Amraie R, Napoleon MA, Yin W, et al. CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2 and
are differentially expressed in lung and kidney epithelial and endothelial cells. bioRxiv 2020.
11. Gardner JP, Durso RJ, Arrigale RR, et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus.
Proc Natl Acad Sci U S A 2003;100:4498-503.
12. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention.
Nat Rev Immunol 2020;20:363-74.
13. Khoo U-S, Chan KYK, Chan VSF, Lin CLS. DC-SIGN and L-SIGN: the SIGNs for infection. J Mol Med (Berl)
2008;86:861-74.
14. da Silva RC, Segat L, Crovella S. Role of DC-SIGN and L-SIGN receptors in HIV-1 vertical transmission. Hum
Immunol 2011;72:305-11.
15. Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat
Med 2020;26:842-4.
16. Wilk AJ, Rustagi A, Zhao NQ, et al. A single-cell atlas of the peripheral immune response in patients with severe
COVID-19. Nat Med 2020;26:1070-6.
17. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020.
18. Cai G, Bosse Y, Xiao F, Kheradmand F, Amos CI. Tobacco Smoking Increases the Lung Gene Expression of ACE2,
the Receptor of SARS-CoV-2. Am J Respir Crit Care Med 2020;201:1557-9.
19. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol 2020;19:767-83.
20. Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus
infections: A systematic review. Clin Neurol Neurosurg 2020;194:105921.
21. Hatterer E, Touret M, Belin MF, Honnorat J, Nataf S. Cerebrospinal fluid dendritic cells infiltrate the brain
parenchyma and target the cervical lymph nodes under neuroinflammatory conditions. PLoS One 2008;3:e3321.
22. Costello F, Dalakas MC. Cranial neuropathies and COVID-19: Neurotropism and autoimmunity. Neurology
2020;95:195-6.
23. Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human
Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell 2020;181:1016-35 e19.
24. Sharma S, Stolina M, Yang SC, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function.
Clin Cancer Res 2003;9:961-8.
25. Huggins A, Paschalidis N, Flower RJ, Perretti M, D'Acquisto F. Annexin-1-deficient dendritic cells acquire a
mature phenotype during differentiation. FASEB J 2009;23:985-96.
26. van Gisbergen KP, Sanchez-Hernandez M, Geijtenbeek TB, van Kooyk Y. Neutrophils mediate immune
modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J Exp Med
2005;201:1281-92.
27. Engering A, Geijtenbeek TB, van Vliet SJ, et al. The dendritic cell-specific adhesion receptor DC-SIGN internalizes

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

antigen for presentation to T cells. J Immunol 2002;168:2118-26.
28. Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus
disease in the early stage. J Transl Med 2020;18:206.
29. Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors:
a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124.
30. Kuppalli K, Rasmussen AL. A glimpse into the eye of the COVID-19 cytokine storm. EBioMedicine
2020;55:102789.
31. Meckiff BJ, RamÃ­rez-SuÃ¡stegui C, Fajardo V, et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive
CD4 T cells in COVID-19. Cell 2020.
32. van Kooyk Y, Geijtenbeek TB. DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol 2003;3:697-709.
33. Milinski M, Croy I, Hummel T, Boehm T. Major histocompatibility complex peptide ligands as olfactory cues in
human body odour assessment. Proc Biol Sci 2013;280:20122889.
34. Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell
Compartment. Cell 2020;182:1419-40 e23.
35. Silvin A, Chapuis N, Dunsmore G, et al. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate
Severe from Mild COVID-19. Cell 2020;182:1401-18 e18.
36. Kaneko N, Kuo HH, Boucau J, et al. The Loss of Bcl-6 Expressing T Follicular Helper Cells and the Absence of
Germinal Centers in COVID-19. SSRN 2020:3652322.
37. Bullwinkel J, Ludemann A, Debarry J, Singh PB. Epigenotype switching at the CD14 and CD209 genes during
differentiation of human monocytes to dendritic cells. Epigenetics 2011;6:45-51.
38. Huttunen R, Heikkinen T, SyrjÃ¤nen J. Smoking and the outcome of infection. J Intern Med 2011;269:258-69.
39. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial
Core Surveillance Team. N Engl J Med 2000;342:681-9.
40. Severance EG, Bossis I, Dickerson FB, et al. Development of a nucleocapsid-based human coronavirus
immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population. Clin Vaccine
Immunol 2008;15:1805-10.
41. Guan W-j, Ni Z-y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv
2020:2020.02.06.20020974.
42. Mick E, Kamm J, Pisco AO, et al. Upper airway gene expression differentiates COVID-19 from other acute
respiratory illnesses and reveals suppression of innate immune responses by SARS-CoV-2. medRxiv 2020.
43. Chua RL, Lukassen S, Trump S, et al. COVID-19 severity correlates with airway epithelium-immune cell
interactions identified by single-cell analysis. Nat Biotechnol 2020;38:970-9.
44. Iwamoto S, Kumamoto T, Azuma E, et al. The effect of azithromycin on the maturation and function of murine
bone marrow-derived dendritic cells. Clin Exp Immunol 2011;166:385-92.
45. Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome. Nature 2018;558:73-9.
46. Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 with Respiratory
Failure. N Engl J Med 2020.
47. Newman AM, Steen CB, Liu CL, et al. Determining cell type abundance and expression from bulk tissues with
digital cytometry. Nat Biotechnol 2019;37:773-82.
48. Cai G, Xiao F. SCANNER: A Web Resource for Annotation, Visualization and Sharing of Single Cell RNA-seq Data.
bioRxiv 2020:2020.01.25.919712.
49. Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas Pan-Cancer
analysis project. Nat Genet 2013;45:1113-20.
50. Bosse Y, Postma DS, Sin DD, et al. Molecular signature of smoking in human lung tissues. Cancer Res
2012;72:3753-63.
51. Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma.
Genome Res 2012;22:2109-19.
52. Landi MT, Dracheva T, Rotunno M, et al. Gene expression signature of cigarette smoking and its role in lung
adenocarcinoma development and survival. PLoS One 2008;3:e1651.
53. Tilley AE, Staudt MR, Salit J, et al. Cigarette Smoking Induces Changes in Airway Epithelial Expression of Genes
Associated with Monogenic Lung Disorders. Am J Respir Crit Care Med 2016;193:215-7.
54. Strulovici-Barel Y, Omberg L, O'Mahony M, et al. Threshold of biologic responses of the small airway epithelium
to low levels of tobacco smoke. Am J Respir Crit Care Med 2010;182:1524-32.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

55. Tilley AE, Harvey BG, Heguy A, et al. Down-regulation of the notch pathway in human airway epithelium in
association with smoking and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179:457-66.
56. Beane J, Sebastiani P, Liu G, Brody JS, Lenburg ME, Spira A. Reversible and permanent effects of tobacco smoke
exposure on airway epithelial gene expression. Genome Biol 2007;8:R201.
57. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide
array probe level data. Biostatistics 2003;4:249-64.
58. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of
digital gene expression data. Bioinformatics 2010;26:139-40.
59. Wang X, Park J, Susztak K, Zhang NR, Li M. Bulk tissue cell type deconvolution with multi-subject single-cell
expression reference. Nat Commun 2019;10:380.
60. Zhang R, Wang Z, Tejera P, et al. Late-onset moderate to severe acute respiratory distress syndrome is associated
with shorter survival and higher mortality: a two-stage association study. Intensive Care Med 2017;43:399-407.
61. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013;29:15-21.
62. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to
genomic features. Bioinformatics 2014;30:923-30.
63. Garcia-Alcalde F, Okonechnikov K, Carbonell J, et al. Qualimap: evaluating next-generation sequencing
alignment data. Bioinformatics 2012;28:2678-9.
64. MJ S, L P, RD K, et al. bcbioRNASeq: R package for bcbio RNA-seq analysis [version 2; peer review: 1 approved,
1 approved with reservations]. F1000Research 2018;6:1976.
65. Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read
counts. Genome Biol 2014;15:R29.
66. Duclos GE, Teixeira VH, Autissier P, et al. Characterizing smoking-induced transcriptional heterogeneity in the
human bronchial epithelium at single-cell resolution. Sci Adv 2019;5:eaaw3413.
67. Reyfman PA, Walter JM, Joshi N, et al. Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into
the Pathobiology of Pulmonary Fibrosis. Am J Respir Crit Care Med 2019;199:1517-36.
68. Madissoon E, Wilbrey-Clark A, Miragaia RJ, et al. scRNA-seq assessment of the human lung, spleen, and
esophagus tissue stability after cold preservation. Genome Biol 2019;21:1.
69. Stuart T, Butler A, Hoffman P, et al. Comprehensive Integration of Single-Cell Data. Cell 2019;177:1888-902 e21.
70. Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I
interferons in development of severe COVID-19. Sci Immunol 2020;5.
71. Aran D, Looney AP, Liu L, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional
profibrotic macrophage. Nat Immunol 2019;20:163-72.
72. Trapnell C, Cacchiarelli D, Grimsby J, et al. The dynamics and regulators of cell fate decisions are revealed by
pseudotemporal ordering of single cells. Nat Biotechnol 2014;32:381-6.
73. Selamat SA, Chung BS, Girard L, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and
integration with mRNA expression. Genome Res 2012;22:1197-211.
74. Ringh MV, Hagemann-Jensen M, Needhamsen M, et al. Tobacco smoking induces changes in true DNA
methylation, hydroxymethylation and gene expression in bronchoalveolar lavage cells. EBioMedicine 2019;46:290304.
75. Sundar IK, Yin Q, Baier BS, et al. DNA methylation profiling in peripheral lung tissues of smokers and patients
with COPD. Clin Epigenetics 2017;9:38.
76. Enfield KSS, Marshall EA, Anderson C, et al. Epithelial tumor suppressor ELF3 is a lineage-specific amplified
oncogene in lung adenocarcinoma. Nat Commun 2019;10:5438.
77. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for
interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
78. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein
annotation. Nucleic Acids Res 2016;44:D457-62.
79. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular
interaction networks. Genome Res 2003;13:2498-504.
80. Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: Network Analysis and Visualization of
Proteomics Data. J Proteome Res 2019;18:623-32.
81. Cai G, Liang S, Zheng X, Xiao F. Local sequence and sequencing depth dependent accuracy of RNA-seq reads.
BMC Bioinformatics 2017;18:364.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

82. Kim JK, Kolodziejczyk AA, Ilicic T, Teichmann SA, Marioni JC. Characterizing noise structure in single-cell RNA-seq
distinguishes genuine from technical stochastic allelic expression. Nat Commun 2015;6:8687.
83. Li J, Witten DM, Johnstone IM, Tibshirani R. Normalization, testing, and false discovery rate estimation for RNAsequencing data. Biostatistics 2012;13:523-38.
84. Carpenter B, Gelman A, Hoffman MD, et al. Stan: A Probabilistic Programming Language. 2017 2017;76:32.
85. Kruschke JK. Bayesian estimation supersedes the t test. J Exp Psychol Gen 2013;142:573-603.
86. Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for searching human genotypephenotype associations. Bioinformatics 2019;35:4851-3.
87. Pividori M, Rajagopal PS, Barbeira A, et al. PhenomeXcan: Mapping the genome to the phenome through the
transcriptome. Sci Adv 2020;6.
88. G. TEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013;45:580-5.
89. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the
human phenome. Elife 2018;7.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure

Figure 1. Correlation and variation of SARS-CoV-2 receptors and immune factors in
nasopharynx/pharynx samples of SARS-CoV-2 ARIs. (A) Scatter plots of gene expression
profiles of SARS-CoV-2 receptor ACE2, immune response activators (CD80, CD83 and CD86),
the proportion of active CD4 memory T cells and M1 macrophages in 22 immune cell types, as
well as scores from a linear model of 5 immune cell types (active CD4 memory T cells, M1 MÃ¸,
mast cells, neutrophils and active DCs). Their associations with viral load are also visualized in
scatter plots. The black and red lines are fits of linear model and LOESS, respectively. (B)

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Hierarchical clustering and heatmap of SARS-CoV-2 receptors, immune factors and proportions
of 5 immune cell types in ARI subsets, including 1 subset with low SARS-CoV-2 load (LoLoad)
and 4 subsets with high SARS-CoV-2 load and activated DCs (DC+), activated T or M1 MÃ¸
(T/MÃ¸+), activated neutrophiles (Neu+) and DC-T/MÃ¸-Neu-. Compared each subset to others,
the fold changes and 95% confidence intervals of each feature are shown on the bottom. The
size of the squares is proportional to the standard deviation.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 2. The effect of smoking on pulmonary gene expression of three SARS-CoV-2
receptors. (A) Forest plots for the effects of smoking on CD209 pulmonary gene expression.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

The top panel shows a comparison of ever-smokers (including current and former smokers) and
nonsmokers, and the bottom panel shows the association of CD209 gene expression with
smoking status (never, former, or current smoker). For each study, pooled effect size, 95% CI
and P values were calculated by meta-analysis. The size of the squares is proportional to the
weights, which were estimated by the standard â€œinverse-varianceâ€ method for random-effects
models in meta-analysis. (B) The expression profiles of ACE2, CD209 and CLEC4M genes in
airways of ever-smokers and non-smokers. For each gene, detection rate (showed by dot size,
larger dot indicates higher detection rate) and expression level (showed by dot color which is
status specific, darker indicates higher expression level) are shown in identified cell types. The
goblet cell in never smokers in the GSE122960 dataset was shown in grey because only a
limited number of cells was detected. Significance: * P<0.05; ** P<0.01; *** P<0.01. Red *
indicates higher expression and blue * indicates lower expression in ever-smokers compared to
never-smokers. (C) The association of lung CD209 methylation with smoking and gene
expression. The left panel shows a forest plot for the effects of smoking on CD209 related
methylation probes in normal lung tissues. For each probe, pooled effect size, 95% CI and P
values were calculated by meta-analysis from available studies, including a: TCGA, b:
GSE32861, c: GSE133062, d: GSE92511 and e: GSE139032. The right panel shows the
correlation between CD209 gene expression levels and measurements of methylation probes
(cg01618851, cg07608333) in normal lung tissues from the GSE32861 study.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 3. The effect of smoking on lung DCs. (A) Forest plots for the effects of smoking on
immune cell composition. For each cell type, the left panel shows a comparison of ever-smoker
(including current and former smokers) and nonsmoker groups, and the right panel shows the
association of the percentage of the cell in 22 immune cells with smoking status (never, former,
or current smoker). For each study, the estimated effect size and 95% confidence intervals (CIs)
are plotted. The size of the squares is proportional to the weights, which were estimated by the
standard â€œinverse-varianceâ€ method for random-effects models in meta-analysis. (B) Violin plots
of the expression of functional markers in DCs from two scRNA-seq datasets. Red P values
indicates higher expression and blue P values indicates lower expression in ever-smokers
compared to never-smokers. (C) Gene expression networks dysregulated in ever-smoker lungs.
The color of a node corresponds to the significance of the gene set (red corresponds to positive
effect; blue corresponds to negative effect). Node size corresponds to the number of genes
within the gene set. Edge weight corresponds to the number of genes found in both connected
gene sets. (D) GSEA enrichment scores of KEGG Asthma and DNA replication pathways. The
top portion of the plot shows the running Enrichment Score (ES) for the gene set, the middle
portion shows the ranks of the members of the gene set in the ranked list of genes
transcriptome wide, and the bottom portion shows the value of the ranking metric in ordered
dataset.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 4. Gene expression differences of three SARS-Cov-2 receptors in upper airway,
lung and blood of healthy and COVID-19 cases. (A) Expression profiles of ACE2, CD209 and
CLEC4M in cell types identified from four scRNA-seq datasets of nasopharynx/pharynx, BALF

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

and PBMC samples from COVID-19 patients and healthy controls. For each dataset, the
detection rate (showed by dot size, larger dot indicates higher detection rate) and expression
level (showed by dot color which is status specific, darker indicates higher expression level) of
each receptor in identified cell types are shown. The gd T cell in never smokers in the
GSE122960 dataset was shown in grey because only a limited number of cells was detected.
(B) The proportions of DCs, macrophages or monocytes in WBC in samples from each
participant. The differences of expression in DCs, monocytes and monocytes were tested in
groups. Significance: * P<0.05; ** P<0.01; *** P<0.01. Red * indicates higher expression and
blue * indicates lower expression in severe cases compared to mild cases, in severe cases
compared to healthy controls, in mild cases compared to healthy controls, in severe cases
compared to asymptomatic cases, in mild cases compared to asymptomatic cases, or in
asymptomatic cases compared to healthy controls.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 5. Dysregulated gene expression networks in lung and blood with COVID-19. Each
node in network is a pie plot showing three comparisons, including mild vs healthy (top right),
severe vs healthy (bottom), and severe vs mild (top left). Node size corresponds to the number
of genes in dataset within the gene set. Color intensity inner the node corresponds to the
significance of the gene set for this dataset (red is for positive effect; blue is for negative effect).
Orange outer circles show the overlapping gene sets found in (A) lung DCs and (B) blood DCs,
while blue outer circles show the uniquely detected gene sets. Edge weight corresponds to the
number of genes found in both connected gene sets. Venn diagrams show the distribution of
significant altered genes more than 2 folds detected from three comparisons in each dataset.
(C) shows STRING networks of changed genes in lung DCs in severe COVID-19 cases
compared to healthy (left) and mild cases (right). The intensity of filling color corresponds to the
log2FC of the gene (red is for positive effect; blue is for negative effect).

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Fig. 6 The expression profiles of functional markers in DCs at three sites. (A) The
expression disparity of markers of maturation (CD83), T-cell stimulation molecules (CD40,
CD80, CD86) and antigen presentation molecules (HLA-DQA2 and FCER1A) in DCs of COVID19 cases and healthy controls. 1 upper airway (nasopharynx/pharynx), 1 lung (BALF) and 2
blood (PBMC) scRNA-seq datasets were analyzed. Significance: * P<0.05; ** P<0.01; ***
P<0.01. Red * indicates higher expression and blue * indicates lower expression in severe
cases compared to mild cases, in severe cases compared to healthy controls, in mild cases
compared to healthy controls, in severe cases compared to asymptomatic cases, in mild cases
compared to asymptomatic cases, or in asymptomatic cases compared to healthy controls.
Despite interest, we did not compare COVID-19 nasopharynx/pharynx samples to healthy
controls due to the limited detection of DCs (N = 1). (B) The dysregulation of gene expression of
MHCII and FcRs in APCs at 3 sites with COVID-19. For each gene, the alteration of gene
expression in APCs of severe COVID-19 cases compared to mild cases, and that in mild
COVID-19 cases compared to healthy controls are visualized in heatmaps. Red indicates
upregulation and blue indicates downregulation. The scale corresponds to log2FC.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Fig. 7 The variation of DC subsets in COVID-19 samples and healthy controls at three
sites. (A) DC subsets identified in single-cell transcriptome profiles from COVID-19 mild and
severe cases and healthy controls. 1 upper airway (nasopharynx/pharynx), 1 lung (BALF) and 2

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

blood (PBMC) scRNA-seq datasets were analyzed. (B) The proportions of DC subsets in
samples from each participant was shown in the top panel for each dataset. The differences of
proportion of each DC subset were tested in groups. Significance: * P<0.05; ** P<0.01. The
bottom panel shows gene expression profile of the T-cell stimulation activators (CD83, CD40,
CD80, CD86), MHCII and FcRs in subsets in samples with different disease status. Red
indicates upregulation and blue indicates downregulation. The scale corresponds to the log2
(normalized scRNA-seq read count) which was centered and scaled by row. (C) Single-cell
trajectory of DCs inferred from scRNA-seq data from BALF and PBMC samples. For each
dataset, the right shows ordered cells from COVID-19 mild and severe cases, and healthy
controls. The left shows ordered cells labeled with identified cell types.

Supplementary File

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S1. The association of SARS-CoV-2 receptors and immune factors with SARSCoV-2 infection and viral load in nasopharynx/pharynx samples of ARIs.
For each feature, results of comparisons between SARS-CoV-2 ARIs and non-viral ARIs are
shown on the left and correlations with SARS-CoV-2 viral load are shown on the right. For each
feature, the estimated coefficient and 95% confidence intervals (CIs) are plotted. Significant P
values which are less than 0.05 were shown in bold.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S2. Correlation matrix among immune cell composition and the expression of
ACE2, CLEC4M and CD209 in ARDS and non-ARDS blood samples. Pairwise similarity
(Spearman correlation) among the expression of candidate genes and 22 immune cells
proportions in ARDS blood samples is shown on the left, and that in non-ARDS blood samples
is shown on the right.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S3. The forest plots for the effects of smoking on ACE2 pulmonary gene
expression.
For each cell type, the top panel shows a comparison of ever-smoker (including current and
former smokers) and nonsmoker groups, and the bottom panel shows the association of the
gene expression with smoking status (never, former, or current smoker). For each study, the
estimated effect size and 95% confidence intervals (CIs) are plotted. The size of the squares is
proportional to the weights, which were estimated by the standard â€œinverse-varianceâ€ method for
random-effects models in meta-analysis.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S4. Clusters of single-cell transcriptomics of bronchial epithelium and lung cells.
For each dataset, the left shows UMAP embedding of single-cell transcriptome profiles from
never smokers and current or ever smokers. The right shows identified cell types.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S5. Expression profiles of cell type markers in scRNA-seq data of bronchial
epithelium and lung cells.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

For each marker, detection rate (showed by dot size, larger dot indicates higher detection rate)
and expression level (showed by dot color which is status specific, darker indicates higher
expression level) are shown in identified cell types.

Figure S6. The forest plot for the effects of smoking on ACE2 related methylation probes
in normal lung tissues.
For each probe, pooled effect size, 95% CI and P values were calculated by meta-analysis from
available studies, including a: TCGA, b: GSE32861, c: GSE133062, d: GSE92511 and e:
GSE139032. For each study, the estimated effect size and 95% confidence intervals (CIs) are
plotted. The size of the squares is proportional to the weights, which were estimated by the
standard â€œinverse-varianceâ€ method for random-effects models in meta-analysis.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S7. The proportion of DCs in WBC of lungs of never and ever smokers. The
proportion of DCs were enumerated from the scRNA-seq data of lung samples of each
participant recruited in two independent studies.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S8. Clusters of single-cell transcriptomics of nasopharynx/pharynx, BALF and
PMBC samples from COVID-19 cases and healthy controls.
For each dataset, the left shows UMAP embedding of single-cell transcriptome profiles from
COVID-19 mild and severe cases, and healthy controls. The right shows identified cell types.

Figure S9. The dysregulation of gene expression of MHCII and FcRs in APCs in blood
with COVID-19. For each gene, the alteration of gene expression in asymptomatic, mild and
severe COVID-19 cases compared to healthy controls are visualized in heatmaps. Red
indicates upregulation and blue indicates downregulation. The scale corresponds to log2FC. The
PBMC scRNA-seq dataset of Lee et al. was analyzed.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S10. Expression profiles of DC subset markers in four scRNA-seq datasets of
nasopharynx/pharynx, BALF and PBMC samples from COVID-19 patients and healthy
controls. For each dataset, the detection rate (showed by dot size, larger dot indicates higher
detection rate) and expression level (showed by dot color, darker indicates higher expression
level) of each cell-type marker are shown in identified DC subtypes.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S11. Integrated single-cell transcriptomics of nasopharynx/pharynx, BALF and
PMBC samples from COVID-19 cases and healthy controls.
The left shows UMAP embedding of single-cell transcriptome profiles from COVID-19 mild and
severe cases, and healthy controls. The right shows identified cell types.

Figure S12. Hierarchical clustering and heatmap of immune cell composition in ARI
nasopharynx/pharynx samples from COVID-19 cases and healthy controls. For each cell

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

type, red indicates relatively higher proportion and blue indicates relatively higher proportion
across samples.

Figure S13. Single-cell trajectory of DCs in COVID-19 nasopharynx/pharynx samples. The
right shows ordered cells from COVID-19 mild and severe cases. The left shows ordered cells
labeled with identified cell types.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure S14. Transcriptional bursting profiles in different DC subsets. The changes in burst
frequency and burst size of HLA genes (blue) and Cox genes (red) in ANXA1+DC compared to
pDC (left) and cDC2 (right) are plotted in log2 scale.

Figure S15. Correlation of genes ACE2, CLEC4M and CD209 in normal lung tissues.
Spearman correlation coefficients for expression of each pair of genes were shown in boxplot.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table S1. Mendelian Randomization inferred causal effect of plasma expression of ACE2,
DC-SIGN and L-SIGN on COVID-19 risk and severity in the European population.

Table S2. The top 100 CD209 expression associated traits identified by GWAS.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table S3. The top 100 CD209 lung expression associated traits identified by PheWAS.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.23.20245316; this version posted December 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table S4. Mendelian Randomization inferred causal effect of plasma expression of DCSIGN on cell count and percentage.

Acknowledgments
This work was supported by University of South Carolina COVID-19 research initiative (G.C.).

Author Contributions
Conceptualization, G.C. and F.X.; Methodology, G.C. and F.X.; Software/Data Analysis, G.C.,
Y.B., M.D, F.Q., X.Y. X.L, X.C.; Investigation, G.C., H.A., M.A., X.Z, J.Z., C.Y., C.C., M.N., P.N.,
D.C., M.W., C.A, and F.X.; Writing â€“ Original Draft, G.C., X.Z., J.Z. and F.X.; Writing â€“ Review &
Editing, G.C., Y.B., M.D., H.A., F.Q., X.Y., X.L., M.A., X.Z., J.Z., X.C., C.Y., C.C., M.N., P.N.,
D.C., M.W., C.A. and F.X.

Declaration of Interests
The authors declare no competing interests.

